NZ571357A - Indolopyridines as EG5 kinesin modulators - Google Patents

Indolopyridines as EG5 kinesin modulators

Info

Publication number
NZ571357A
NZ571357A NZ571357A NZ57135707A NZ571357A NZ 571357 A NZ571357 A NZ 571357A NZ 571357 A NZ571357 A NZ 571357A NZ 57135707 A NZ57135707 A NZ 57135707A NZ 571357 A NZ571357 A NZ 571357A
Authority
NZ
New Zealand
Prior art keywords
disclosed
indolopyridines
compound
formula
kinesin
Prior art date
Application number
NZ571357A
Other languages
English (en)
Inventor
Matthias Vennemann
Thomas Bar
Jurgen Braunger
Astrid Zimmermann
Volker Gekeler
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of NZ571357A publication Critical patent/NZ571357A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ571357A 2006-02-22 2007-02-21 Indolopyridines as EG5 kinesin modulators NZ571357A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06110295 2006-02-22
EP06119038 2006-08-16
PCT/EP2007/051688 WO2007096393A1 (en) 2006-02-22 2007-02-21 Indolopyridines as eg5 kinesin modulators

Publications (1)

Publication Number Publication Date
NZ571357A true NZ571357A (en) 2010-11-26

Family

ID=37964159

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ571357A NZ571357A (en) 2006-02-22 2007-02-21 Indolopyridines as EG5 kinesin modulators

Country Status (18)

Country Link
US (1) US8530493B2 (cg-RX-API-DMAC7.html)
EP (3) EP1996592B1 (cg-RX-API-DMAC7.html)
JP (1) JP5349056B2 (cg-RX-API-DMAC7.html)
KR (1) KR101415354B1 (cg-RX-API-DMAC7.html)
CN (1) CN101389628B (cg-RX-API-DMAC7.html)
AR (1) AR059609A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007217560B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0708233A2 (cg-RX-API-DMAC7.html)
CA (1) CA2643488C (cg-RX-API-DMAC7.html)
EA (1) EA015150B1 (cg-RX-API-DMAC7.html)
HK (1) HK1205510A1 (cg-RX-API-DMAC7.html)
IL (1) IL193625A (cg-RX-API-DMAC7.html)
MX (1) MX2008010801A (cg-RX-API-DMAC7.html)
NZ (1) NZ571357A (cg-RX-API-DMAC7.html)
TW (1) TWI377207B (cg-RX-API-DMAC7.html)
UA (1) UA96592C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007096393A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200808070B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US7838524B2 (en) 2004-04-30 2010-11-23 Bayer Healthcare Llc Substituted pyrazolyl urea derivatives useful in the treatment of cancer
DE602005024572D1 (de) 2004-08-18 2010-12-16 4Sc Ag Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
SI1901729T1 (sl) * 2005-05-13 2012-05-31 Topotarget Uk Ltd Farmacevtske formulacije HDAC inhibitorjev
CA2627923C (en) * 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
EP2033962A1 (en) * 2007-08-22 2009-03-11 4Sc Ag Tetracyclic indolopyridines as EG5 inhibitors
CN101868446A (zh) * 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
EP2098524A1 (en) * 2008-03-05 2009-09-09 4Sc Ag Process for preparing enantiomerically pure indolopyrinidines
SI2262493T1 (sl) * 2008-03-07 2015-07-31 Onxeo Dk Branch Of Onxeo S.A. France Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
CN109467555A (zh) * 2018-06-21 2019-03-15 广东蓝堡生物科技有限公司 一种他达那非衍生物及其制备方法和应用
CN109160914B (zh) * 2018-11-17 2020-06-16 重庆文理学院 一种双吲哚并吡啶类衍生物的合成方法及在抗肿瘤中的应用
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途
CN113577063B (zh) * 2021-08-30 2022-08-16 广州领晟医疗科技有限公司 一种化合物在制备治疗炎性肠病的药物中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0357122A3 (en) 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
DE19744257B4 (de) 1997-10-07 2004-04-15 Zentaris Gmbh Beta-Carboline und deren Verwendung zur Behandlung von malignen und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen
US6890933B1 (en) 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
AU2002213421A1 (en) 2000-10-03 2002-04-15 Lilly Icos Llc Condensed pyridoindole derivatives
WO2002095361A2 (en) 2001-05-22 2002-11-28 President And Fellows Of Harvard College Identification of anti-protozoal agents
CA2460939C (en) 2001-09-19 2008-07-29 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
EP2292615A1 (en) 2002-02-01 2011-03-09 AstraZeneca AB Quinazoline compounds
AU2003247891A1 (en) 2002-07-08 2004-01-23 Merck & Co., Inc. Mitotic kinesin binding site
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
JP4580932B2 (ja) 2003-06-12 2010-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤のプロドラッグ
CN1960725A (zh) 2004-03-15 2007-05-09 Ptc医疗公司 用于抑制血管发生的四环咔啉衍生物
DE602005024572D1 (de) * 2004-08-18 2010-12-16 4Sc Ag Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
AU2006212863A1 (en) 2005-02-10 2006-08-17 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2007144384A1 (en) 2006-06-14 2007-12-21 4Sc Ag Pyrazolopyrimidones
WO2008006883A2 (en) 2006-07-13 2008-01-17 4Sc Ag Benzopyranopyrazoles

Also Published As

Publication number Publication date
TW200815441A (en) 2008-04-01
EP1996592B1 (en) 2014-08-27
HK1205510A1 (en) 2015-12-18
EP2824105B1 (en) 2021-03-31
EA200801739A1 (ru) 2009-04-28
IL193625A0 (en) 2009-05-04
US20090233902A1 (en) 2009-09-17
IL193625A (en) 2015-01-29
CN101389628A (zh) 2009-03-18
CA2643488A1 (en) 2007-08-30
AU2007217560A1 (en) 2007-08-30
AR059609A1 (es) 2008-04-16
UA96592C2 (uk) 2011-11-25
BRPI0708233A2 (pt) 2011-05-24
KR101415354B1 (ko) 2014-07-04
MX2008010801A (es) 2008-09-05
CN101389628B (zh) 2013-02-27
US8530493B2 (en) 2013-09-10
EA015150B1 (ru) 2011-06-30
EP1996592A1 (en) 2008-12-03
CA2643488C (en) 2014-08-05
ZA200808070B (en) 2014-03-26
JP5349056B2 (ja) 2013-11-20
EP2824105A1 (en) 2015-01-14
KR20080098043A (ko) 2008-11-06
AU2007217560B2 (en) 2012-06-28
TWI377207B (en) 2012-11-21
JP2009527533A (ja) 2009-07-30
WO2007096393A1 (en) 2007-08-30
EP3862354A1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
UA100684C2 (uk) Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
MY149716A (en) Pyridazine derivatives as smo inhibitors
WO2011019634A3 (en) Aryl substituted sulfonamide compounds and their use as anticancer agents
NZ609309A (en) Redox drug derivatives
MX2013012265A (es) Carboxamidas que modulan el receptor de androgeno.
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
MX2010000502A (es) Compuestos y metodos para modular fxr.
TN2015000102A1 (en) Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors
NZ598747A (en) Androgen receptor modulating compounds
EA201200102A1 (ru) Соединения, применимые в качестве лекарственных средств
MD4371B1 (ro) Derivaţi de benzo¢f]¢1,4]oxazepin-5-one ca modulatori ai canalelor ionice
MX2012013274A (es) Novedosos derivados de la pirimidina.
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
MX2009012271A (es) Compuestos antagonistas de acido ribonucleico para la modulacion de her3.
EA029089B9 (ru) Модуляторы метил-модифицирующих ферментов, композиции и их применение
NZ615270A (en) Phosphoramidate derivatives of 5 - fluoro - 2 ‘ - deoxyuridine for use in the treatment of cancer
MY166026A (en) Tetrahydro-pyrido-pyrimidine derivatives
GB2433070A (en) Porphyrin derivatives and their use in photon activation therapy
NZ589191A (en) Quinazoline derivatives that inhibit the activity of egfr
SG170041A1 (en) Methods for cancer therapy and stem cell modulation
MX2009011421A (es) Derivados de ftalazina e isoquinolina con actividades moduladoras del receptor de la s1p.
MX343773B (es) Uso de ligandos sigma en dolor por cancer de huesos.
MX2011012068A (es) Nucleosidos 2'-fluoro arabino y su utilizaicon.
MXPA06000957A (es) Compuestos de n-sulfonil heterociclopirrolilalquilamina como ligandos de 5-hidroxitriptamina-6.
MX353062B (es) Nuevas carboxamidas heterociclicas como moduladores de la activadad de cinasas.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 FEB 2017 BY PAVIS EG

Effective date: 20140219

LAPS Patent lapsed